Biocon's Kiran Mazumdar Shaw said the company deliberately took a hit on its topline in order to rationalize products. Biocon is focusing towards being a specialized products player.
first published: Apr 30, 2015 12:10 pm
A collection of the most-viewed Moneycontrol videos.

New Year Party Or Year-End Blues? Bulls In Focus| Top Stock Bets & 2026 Outlook| Opening Bell Live

Nifty Trades in a Narrow 100-Point Range on 2025’s Final F&O Expiry | Closing Bell Live

Small-Caps & Risk: What Investors Often Miss

Nifty’s Best Case Target & Top Stock Bets For 2026| IPO Wave Set To Get Bigger| Opening Bell Live
You are already a Moneycontrol Pro user.

